<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_content=101560960&amp;utm_source=Chrome&amp;fc=None&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20250127131342&amp;utm_campaign=journals<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_content=101560960&amp;utm_source=Chrome&amp;fc=None&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20250127131342&amp;utm_campaign=journals" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> 2025年1月27日星期一18:13:42 +0000</lastbuilddate><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>探索使用HBSAG预测干扰素治疗方案以实现慢性丙型肝炎患者的临床治疗：一项临床研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867915/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>结论：慢性丙型肝炎患者的基线HBSAG是延长IFN治疗过程的危险因素，其相关性正相关。最终，可以建立基于基线HBSAG水平的个性化模型，以在治疗开始之前大致估算干扰素治疗的持续时间，从而指导临床决策。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1528758。 doi：10.3389/fimmu.2024.1528758。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：尽管用于慢性乙型肝炎的类乙二醇化干扰素α-2b（PEG-IFNα-2B）疗法受到了越来越多的关注，但确定最佳治疗方法仍然具有挑战性。这项研究旨在开发一个预测干扰素（IFN）治疗课程的有效模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从2018年1月至2023年12月，在天津第三中央医院招募了慢性丙型肝炎患者，接受PEG-IFNα-2B单一疗法或与NAS（核苷类似物）结合的患者。所有患者在治疗后都获得了丙型肝炎表面抗原（HBSAG）清除。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：该研究招募了176例慢性肝炎患者，IFN治疗过程中位数为35.23±25.22周。它们以7：3的比例随机分为两个队列。培训队列中有123例患者，验证队列中有53例患者。单变量和多变量分析表明，基线HBSAG，12周HBSAG和肝硬化的存在显着影响IFN治疗过程，两者都是危险因素（β= 7.27,4.27,10.91; p &lt;0.05）。调整了混杂因素后，HBSAG仍然是一个重要的预测因子（β= 6.99，95％CI：3.59,10.40; p &lt;0.05），最终包括在内以建立模型。验证队列中的实际和预测值高度匹配，同时计算了验证队列的平均绝对百分比误差（MAPE），均方根误差（RMSE）和精度（ACC）。外部验证还表明该模型可以用作初始评估的工具。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：慢性丙型肝炎患者的基线HBSAG是延长IFN治疗过程的危险因素，其相关性正相关。最终，可以建立基于基线HBSAG水平的个性化模型，以在治疗开始之前大致估算干扰素治疗的持续时间，从而指导临床决策。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867915/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867915</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11758162/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11758162</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1528758>10.3389/fimmu.2024.1528758</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867915</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Fei Yan</dc:creator><dc:creator> Fei Tang</dc:creator><dc:creator> Jing Chen</dc:creator><dc:creator> Yicheng Lin</dc:creator><dc:creator> Xinyu Chen</dc:creator><dc:creator>秦杜</dc:creator><dc:creator>威利·阴</dc:creator><dc:creator>Jing Liang</dc:creator><dc:creator> Lei Liu</dc:creator><dc:creator>方王</dc:creator><dc:creator>Baiguo Xu</dc:creator><dc:creator>清</dc:creator><dc:creator>武士</dc:creator><dc:date>2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>探索使用HBSAG预测干扰素治疗方案以实现慢性丙型肝炎患者的临床治疗：一项临床研究</dc:title><dc:identifier>PMID：39867915</dc:identifier><dc:identifier> PMC：PMC11758162</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1528758</dc:identifier></item><item><title>对三阴性乳腺癌治疗中肿瘤免疫微环境的传统中药调节的机械探索：基于Citepsace和Bioinformitics分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867914/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>结论：TCM在TNBC中的治疗作用主要涉及肿瘤微环境中的免疫调节，特别是通过调节CD8+和CD4+ T细胞的调节。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1443648。 doi：10.3389/fimmu.2024.1443648。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：三阴性乳腺癌（TNBC）是一种高度侵略性的乳腺癌亚型，其特征是尽管基于化学疗法的治疗，但经常复发，转移和生存结果差。这项研究旨在研究中药（TCM）调节TNBC中肿瘤免疫微环境的机制，利用CiteSpace和生物信息学分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们采用Citespace来分析治疗热点和关键的TCM配方，然后进行生物信息学分析，以识别主要的活性成分，目标，相关途径及其在TNBC治疗中的临床意义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：Citespace分析突出了关键的TCM配方，包括Sanhuang汤。网络药理学鉴定了主要的生物活性成分，例如肌肉成分，物理学二葡萄糖苷，procyanidin b-5,3&#39;-o-gallate，Gallic Acid-3-o-（6&#39;-o-galloyl）---葡萄糖苷和葡萄糖糖苷和isomucronulatol-7,2&#39; -DI-O-葡萄糖二烯，具有包括有丝分裂原激活蛋白激酶1（MAPK1），Janus激酶2（JAK2）和淋巴细胞特异性蛋白酪氨酸激酶（LCK）的核心靶标。发现这些靶标参与免疫调节，特别是CD8+和CD4+ T细胞的调节。另外，核心靶标与TNBC患者的无复发生存率（RF）和总生存期（OS）有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：TCM在TNBC中的治疗作用主要涉及肿瘤微环境中的免疫调节，特别是通过调节CD8+和CD4+ T细胞的调节。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867914/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867914</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757242/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757242</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1443648>10.3389/fimmu.2024.1443648</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867914</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator>丹丹冯</dc:creator><dc:creator>dongqing pu</dc:creator><dc:creator> Jinlu Ren</dc:creator><dc:creator>明刘</dc:creator><dc:creator>小小的太阳</dc:creator><dc:creator>张张</dc:creator><dc:creator>Jingwei li</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>对三阴性乳腺癌治疗中肿瘤免疫微环境的传统中药调节的机械探索：基于Citepsace和Bioinformitics分析</dc:title><dc:identifier>PMID：39867914</dc:identifier><dc:identifier> PMC：PMC11757242</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1443648</dc:identifier></item><item><title> SCRNA-Seq揭示了与胶质瘤相关的巨噬细胞的功能特征以及氯化酸对基于小鼠模型和临床实践的免疫微环境研究的调节作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>简介：神经胶质瘤是最常见的原发性恶性脑肿瘤。尽管手术技术和治疗方案取得了进步，但神经胶质瘤的治疗作用仍然不令人满意。免疫疗法为神经胶质瘤患者带来了新的希望，但其治疗结果受到肿瘤微环境（TME）的免疫抑制性质的限制。这项研究旨在揭示与肿瘤相关巨噬细胞（TAM）的亚群和功能特征，并探索调节性... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1494806。 doi：10.3389/fimmu.2024.1494806。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：神经胶质瘤是最常见的原发性恶性脑肿瘤。尽管手术技术和治疗方案取得了进步，但神经胶质瘤的治疗作用仍然不令人满意。免疫疗法为神经胶质瘤患者带来了新的希望，但其治疗结果受到肿瘤微环境（TME）的免疫抑制性质的限制。这项研究旨在揭示与肿瘤相关巨噬细胞（TAM）的亚群和功能特征，并探索绿原酸（CHA）对免疫微环境的调节作用，以及其临床应用的潜力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，CHA用于模型小鼠。进行SCRNA- SEQ分析以阐明骨髓的分化轨迹和功能特征 - 衍生的单噬细胞（BMDMS）和小胶质细胞。使用目标预测数据库构建了PPI和分子对接模型。审查了接受CHA治疗的患者的病例。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CHA减慢了模型小鼠的肿瘤生长，并延长了小鼠的存活时间。它增强了巨噬细胞的抗原 - 表现功能和T-细胞免疫激活 - 相关的基因表达，通过JAK -STAT途径激活了小胶质细胞，并改善了抗肿瘤功能。 CHA与STAT1的良好亲和力得到了证实。接受CHA治疗的患者存活了5年零6个月，在治疗9个月后，可以进行部分缓解（PR），并且在没有任何新症状或有毒副作用的情况下保持活力。我们的研究揭示了TAM的亚型和分化轨迹。 CHA通过调节BMDM和小胶质细胞的功能来显着改善神经胶质瘤的免疫微环境。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：这项研究可能会提供针对TME调节的新见解，并为CHA的临床应用提供理论和实际支持。结果表明，CHA在改善免疫微环境和抗肿瘤作用方面的潜力，这可能对未来的神经胶质瘤治疗策略有影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867913/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867913</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757274/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757274</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1494806>10.3389/fimmu.2024.1494806</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867913</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator>王王</dc:creator><dc:creator>Shenglan Li</dc:creator><dc:creator> Yuxiao Chen</dc:creator><dc:creator> Jinyi Chen</dc:creator><dc:creator>可以王</dc:creator><dc:creator>Zhuang Kang</dc:creator><dc:creator> Mengqian Huang</dc:creator><dc:creator> Zehao Cai</dc:creator><dc:creator> Yuxiang粉丝</dc:creator><dc:creator>Yanjie lan</dc:creator><dc:creator> Yumeng Yu</dc:creator><dc:creator> Ruijing Bai</dc:creator><dc:creator>冯陈</dc:creator><dc:creator>江江</dc:creator><dc:creator>温宾·李</dc:creator><dc:date>2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>SCRNA-Seq揭示了与胶质瘤相关的巨噬细胞的功能特征以及氯化酸对基于小鼠模型和临床实践的免疫微环境研究的调节作用</dc:title><dc:identifier>PMID：39867913</dc:identifier><dc:identifier> PMC：PMC11757274</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1494806</dc:identifier></item><item><title>在T淋巴细胞上腐蚀OX40的OX40-配合融合蛋白的产生和表征</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description> OX40是肿瘤坏死因子（TNF）受体超家族的成员，在活化的T细胞表面表达。在与其同源配体相互作用后，OX40L，OX40将共刺激信号传输到抗原引发的T细胞，从而促进其激活，分化和存活^（ - ）过程对于建立自适应免疫必不可少的过程。尽管OX40-OX40L相互作用已在疾病治疗的背景下进行了广泛的研究，但开发了... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1473815。 doi：10.3389/fimmu.2024.1473815。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OX40是肿瘤坏死因子（TNF）受体超家族的成员，在活化的T细胞表面表达。与其同源配体相互作用OX40L后，OX40将共刺激信号传输到抗原培养的T细胞，从而促进其激活，分化和存活<sup>-</sup>对建立适应性免疫必不可少的过程。尽管在疾病治疗的背景下已经对OX40-OX40L的相互作用进行了广泛的研究，但开发了自然表达的膜结合的OX40L的替代品，尤其是多层化的OX40L夹子，有效地调节了OX40驱动的T细胞反应仍然是一个重大挑战。在这项研究中，我们成功地设计了能够在T细胞上鲁棒激活OX40的可溶性OX40L融合蛋白。这是通过将功能性多聚化结构域纳入OX40L的TNF同源域中实现的。这些OX40L蛋白与OX40结合，随后激活NF-κB信号传导，并<i>在体外</i>诱导T细胞诱导细胞因子的产生。<i>在体内</i>，用OX40L融合蛋白之一处理的小鼠<sup>-</sup>包含与人IgG1 Fc结构域的C末端相关的单链OX40L三聚体，形成了三聚体的二聚体<sup>-</sup>表现出显着增强<sup>+</sup> T细胞在免疫反应的一级阶段。可比较的抗体融合单链TNF蛋白，掺入4-1BBL，CD70（CD27L）或GITRL代替OX40L代替<i>体内</i>T细胞反应中相似的OX40L。因此，我们建议，通过创新的设计策略优化OX40L蛋白的多聚化可能有助于开发更有效的靶向免疫疗法激动剂。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867912/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867912</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757143/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757143</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1473815>10.3389/fimmu.2024.1473815</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867912</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Ayaka Sato</dc:creator><dc:creator> Hodaka Nagai</dc:creator><dc:creator> Ayano Suzuki</dc:creator><dc:creator>嗯</dc:creator><dc:creator>Shimpei Matsuyama</dc:creator><dc:creator> nagito shibui</dc:creator><dc:creator> Masashi Morita</dc:creator><dc:creator> Mari Hikosaka-Kuniishi</dc:creator><dc:creator> Naoto ishii</dc:creator><dc:creator> Takanori如此</dc:creator><dc:date>2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>在T淋巴细胞上腐蚀OX40的OX40-配合融合蛋白的产生和表征</dc:title><dc:identifier>PMID：39867912</dc:identifier><dc:identifier> PMC：PMC11757143</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1473815</dc:identifier></item><item><title> ARP2/3复合亚基的Pan-Cancer分析：关注ARPC1A的作用并验证非小细胞肺癌中的ARPC1A/C-MYC轴</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867911/？<description>结论：我们的研究为靶向ARP2/3复杂亚基作为抗癌策略提供了新的见解，并强调了ARPC1A作为肿瘤诊断，预后和免疫治疗反应预测的新型生物标志物的潜力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1491910。 doi：10.3389/fimmu.2024.1491910。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：ARP2/3复合物是肿瘤转移的关键调节剂，靶向其亚基为抗转移治疗提供了潜力。但是，表达曲线，预后相关性以及其在癌症中的亚基的诊断价值仍然很少。这项研究旨在研究PAN-CACTER中ARP2/3复合亚基，尤其是ARPC1A的临床相关性，并进一步分析ARPC1A的潜在生物学机制，及其与免疫浸润和化学疗法药物敏感性的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：探索ARP2/3复杂亚基的差异表达及其在癌症之间的临床相关性，我们分析了来自TCGA和GTEX数据库的数据。使用TCPA和TIMER2.0数据库检查了ARPC1A与免疫浸润及其与功能蛋白的相互作用之间的关系。进行基因集富集分析（GSEA）以鉴定与ARPC1A相关的信号通路。使用CellMiner，GDSC和CTRP数据库评估了与ARPC1A表达相关的化学疗法药物敏感性。通过定量PCR（QPCR）和Western blot验证了ARPC1A对C-MYC表达的影响。最后，使用CCK-8，EDU掺入，菌落形成和Transwell分析，进一步验证了ARPC1A在非小细胞肺癌（NSCLC）细胞中的生物学作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：ARP2/3复杂亚基，尤其是ARPC1A，在大多数癌症中经常过表达，与预后不良的结果相关，并显示出明显的诊断效用。拷贝数变化可能在ARP2/3复杂亚基表达的失调中起作用。小分子X4.5.Dianilimophthalimide在Pan-Canter的情况下表现出作为靶向治疗剂的希望。功能预测表明，ARPC1A与氧化磷酸化途径和与细胞增殖相关的信号通路有关，包括由MYC介导的途径，ASN可能充当上游调节剂。此外，ARPC1A已与包括吉非替尼在内的化学疗法药物的抗性有关。<i>体外</i>实验证实了ARPC1A可以通过调节C-MYC表达来增强非小细胞肺癌（NSCLC）细胞中的恶性表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究为靶向ARP2/3复杂亚基作为抗癌策略提供了新的见解，并强调了ARPC1A作为肿瘤诊断，预后和免疫治疗反应预测的新型生物标志物的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867911/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867911</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11759278/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11759278</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1491910>10.3389/fimmu.2024.1491910</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867911</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Chenkang周</dc:creator><dc:creator>Yuxin Chen</dc:creator><dc:creator> Shuhui Chen</dc:creator><dc:creator> lijuan hu</dc:creator><dc:creator> Junjun Wang</dc:creator><dc:creator> Yumin Wang</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>ARP2/3复合亚基的Pan-Cancer分析：关注ARPC1A的作用并验证非小细胞肺癌中的ARPC1A/C-MYC轴</dc:title><dc:identifier>PMID：39867911</dc:identifier><dc:identifier> PMC：PMC11759278</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1491910</dc:identifier></item><item><title> Medaka淋巴细胞的单细胞转录组分析显示，胸腺中没有完全成熟的T细胞，而肾脏中的T-Linege承诺不存在</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867910/？<description>淋巴细胞发育的细胞和分子机制在硬质物种中是多种多样的。尽管最近对斑马鱼造血细胞的SCRNA-SEQ分析已经提出了我们对遗产造血的理解，但使用另一种遗传模型Medaka进行了比较研究，该模型（在硬骨鱼之间进化上是遥远的），对于理解定虫中的共同点和物种特异性很有用。为了深入了解...的分子和细胞机制如何</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1517467。 doi：10.3389/fimmu.2024.1517467。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">淋巴细胞发育的细胞和分子机制在硬质物种中是多种多样的。尽管最近对斑马鱼造血细胞的SCRNA-SEQ分析已经提出了我们对遗产造血的理解，但使用另一种遗传模型Medaka进行了比较研究，该模型（在硬骨鱼之间进化上是遥远的），对于理解定虫中的共同点和物种特异性很有用。为了深入了解Medaka和斑马鱼中淋巴细胞发育的不同分子和细胞机制，我们建立了一个<i>重组激活基因1</i> （ <i>RAG1</i> ）突变体Medaka，在V（d）J重排的淋巴细胞抗原受体基因中表现出缺陷，缺乏成熟的B和T细胞。胸腺和肾脏中野生型和<i>RAG1</i>突变体淋巴细胞的SCRNA-SEQ分析表征了T和B细胞的发育阶段，发现大多数开发的<i>CD4 <sup>+</sup> <sup>CD8-</sup></i>和CD4-和<i>CD4- CD8 <sup>+</sup> CD8 <sup>+</sup></i>单阳性（SP）T细胞种群在胸腺中不存在，并鉴定出已经致力于肾脏T谱系的淋巴样祖细胞，这意味着Medaka淋巴细胞发育的独特特征。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867910/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867910</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11759298/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11759298</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1517467>10.3389/fimmu.2024.1517467</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867910</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Hiyori Sakaguchi</dc:creator><dc:creator> Masaru Matsuda</dc:creator><dc:creator> Norimasa Iwanami</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Medaka淋巴细胞的单细胞转录组分析显示，胸腺中没有完全成熟的T细胞，而肾脏中的T-Linege承诺不存在</dc:title><dc:identifier>PMID：39867910</dc:identifier><dc:identifier> PMC：PMC11759298</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1517467</dc:identifier></item><item><title>三阴性乳腺癌的糖基化分析：临床和免疫相关性以及LMAN1L作为生物标志物和治疗靶标的鉴定</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>简介：乳腺癌（BC）是女性最普遍的恶性肿瘤，三阴性乳腺癌（TNBC）显示所有亚型的预后最差。糖基化越来越多地被认为是肿瘤微环境中的关键生物标志物，尤其是在卑诗省。但是，尚未定义与TNBC相关的糖基化相关基因。此外，尚未深入研究它们的特征和与预后的关系。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日; 15：1521930。 doi：10.3389/fimmu.2024.1521930。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：乳腺癌（BC）是女性最普遍的恶性肿瘤，三阴性乳腺癌（TNBC）显示所有亚型的预后最差。糖基化越来越多地被认为是肿瘤微环境中的关键生物标志物，尤其是在卑诗省。但是，尚未定义与TNBC相关的糖基化相关基因。此外，尚未深入研究它们的特征和与预后的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用转录组分析来识别与TNBC预后相关的糖基化相关签名（GRS）。在多个独立数据集中构建并验证了基于机器学习的预测模型。该模型的预测能力扩展了以评估TNBC个体的预后，肿瘤免疫微环境和免疫疗法反应。 <i>LMAN1L</i> （凝集素，甘露糖结合1）被确定为TNBC中的新型预后标记，其生物学作用通过实验测定得到了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：GRS与TNBC患者显示出显着的预后相关性。风险模型有效地预测了分子特征，包括免疫细胞浸润和对免疫疗法的潜在反应。实验验证证实<i>LMAN1L</i>是一种新型糖基化相关的预后基因，低表达显着抑制了TNBC细胞增殖和迁移。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：我们的GRS风险模型证明了TNBC预后和免疫疗法反应的强大预测能力。该模型为TNBC中的个性化治疗和改善的临床结果提供了有希望的策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867909/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867909</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11759290/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11759290</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1521930>10.3389/fimmu.2024.1521930</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867909</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Qianru yu</dc:creator><dc:creator>汉尼·恩</dc:creator><dc:creator>新闻朱</dc:creator><dc:creator>Chang Liu</dc:creator><dc:creator> Xin Zhang</dc:creator><dc:creator>王王</dc:creator><dc:creator>Zongyao li</dc:creator><dc:creator> Songchang Shi</dc:creator><dc:creator> Haoran Zhao</dc:creator><dc:creator>西克西安·周（Cixiang Zhou）</dc:creator><dc:creator> Qian Zhao</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>三阴性乳腺癌的糖基化分析：临床和免疫相关性以及LMAN1L作为生物标志物和治疗靶标的鉴定</dc:title><dc:identifier>PMID：39867909</dc:identifier><dc:identifier> PMC：PMC11759290</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1521930</dc:identifier></item><item><title> M5C甲基化修饰可以是结直肠癌的同谋</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>结直肠癌（CRC）是世界上最普遍的恶性肿瘤之一，其发生和发育与复杂的免疫调节机制密切相关。作为人体防御的第一个障碍，先天免疫在肿瘤免疫监测和抗肿瘤反应中起着关键作用，其中I/III型干扰素（IFN）是具有重要抗病毒和抗肿瘤功能的重要介体。 RNA的5-甲基胞嘧啶（M5C）的修饰是关键的表观遗传... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1512353。 doi：10.3389/fimmu.2024.1512353。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结直肠癌（CRC）是世界上最普遍的恶性肿瘤之一，其发生和发育与复杂的免疫调节机制密切相关。作为人体防御的第一个障碍，先天免疫在肿瘤免疫监测和抗肿瘤反应中起着关键作用，其中I/III型干扰素（IFN）是具有重要抗病毒和抗肿瘤功能的重要介体。 RNA的5-甲基胞嘧啶（M5C）修饰是一种关键的表观遗传调节，可促进CRC癌基因和免疫相关基因的表达。它可以通过影响mRNA稳定性，翻译效率和核输出来增强肿瘤细胞的增殖，迁移和侵袭。此外，M5C修饰调节先天免疫信号通路的活性，并抑制干扰素的产生和功能，进一步帮助肿瘤细胞逃避免疫监测。但是，关于M5C修饰与CRC先天免疫之间的相互作用的阐明不足。在这项研究中，对结直肠癌的干扰素I/III机制进行了系统的审查和探索。这项工作的重点是M5C修饰如何通过影响干扰素信号通路来促进肿瘤免疫逃逸，从而为临床使用提供新的诊断标记和治疗靶标，并提高免疫疗法的功效。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867908/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867908</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757137/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757137</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1512353>10.3389/fimmu.2024.1512353</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867908</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> yiqi太阳</dc:creator><dc:creator>云菲</dc:creator><dc:creator>吕江</dc:creator><dc:creator>Chao Zhong</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>M5C甲基化修饰可以是结直肠癌的同谋</dc:title><dc:identifier>PMID：39867908</dc:identifier><dc:identifier> PMC：PMC11757137</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1512353</dc:identifier></item><item><title>全身性红斑狼疮的骨髓长期浆细胞中的干扰素激活</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867907/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = 4<description>虽然长期浆细胞（LLPC）群体的耐用抗体反应对于防止病原体很重要，但如果在自身免疫性疾病（例如全身性红斑lupus slematosus）（SLE）（SLE）（SLE）（SLE）（SLE）中发生的自身免疫性疾病（例如，LLPC）可能会有害。 ）。因此，消除自动反应性LLPC可以改善抗体驱动的自身免疫性疾病的治疗。但是，LLPC仍然是一个具有挑战性的治疗靶点。在这里，我们比较了匹配的骨头... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1499551。 doi：10.3389/fimmu.2024.1499551。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">虽然长期浆细胞（LLPC）群体的耐用抗体反应对于防止病原体很重要，但如果在自身免疫性疾病（例如全身性红斑lupus slematosus）（SLE）（SLE）（SLE）（SLE）（SLE）中发生的自身免疫性疾病（例如，LLPC）可能会有害。 ）。因此，消除自动反应性LLPC可以改善抗体驱动的自身免疫性疾病的治疗。但是，LLPC仍然是一个具有挑战性的治疗靶点。在这里，我们比较了匹配的骨髓（BM）和外围血（PBL）血浆细胞（PC）SLE和健康供体（HD）的室。我们在SLE和HD BM之间显示了CD138-和CD138+ PC的相似分布，包括推定的LLPC（CD19- CD138+ CD38+）。对于SLE和HD，CD138+ PC在BM中的频率高于PBL。 KI-67与PBL隔室的表达相关，在所有PC子集上都发现它，而不论CD19或CD138表达如何。转录组分析鉴定了SLE BM中的过渡B细胞中的干扰素（IFN）基因特征，但同样令人惊讶的是来自SLE的BM PC。 BM PC和B细胞响应于I型IFN刺激<i>而磷酸化</i>的STAT1磷酸化，但与PBL相比，折叠变化减少。 BM PC结合了I型IFN受体阻滞抗体阳极单抗，但它比循环B细胞的程度较小。抗核自身抗体（ANA）在SLE患者的BM上清液和PBL血清中发现。与PBL对应物相比，SLE和HD BM衍生的PC的生存率都增加了。总而言之，这些发现显示了SLE中BM PC中IFN激活的证据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867907/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867907</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757124/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757124</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1499551>10.3389/fimmu.2024.1499551</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867907</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Diana F Alzamareh</dc:creator><dc:creator>尼达·梅德努（Nida Meednu）</dc:creator><dc:creator> Neha Nandedkar-Kulkarni</dc:creator><dc:creator> Daria Krenitsky</dc:creator><dc:creator>詹妮弗·巴纳德（Jennifer Barnard）</dc:creator><dc:creator>肯·雅萨卡（Ken Yasaka）</dc:creator><dc:creator>韦斯利·杜雷特（Wesley Durrett）</dc:creator><dc:creator> Juilee Thakar</dc:creator><dc:creator>哈维尔·兰格·莫雷诺（Javier Rangel-Moreno）</dc:creator><dc:creator>詹妮弗·H·阿诺利克（Jennifer H Anolik）</dc:creator><dc:creator>詹妮弗·巴纳斯（Jennifer L Barnas）</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>全身性红斑狼疮的骨髓长期浆细胞中的干扰素激活</dc:title><dc:identifier>PMID：39867907</dc:identifier><dc:identifier> PMC：PMC11757124</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1499551</dc:identifier></item><item><title>婴儿呼吸道感染调节母乳淋巴细胞</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>结论：护理婴儿的呼吸道感染刺激了母乳中细胞因子和趋化因子的增加，从而促进淋巴细胞的募集和激活。该过程可能会促进免疫耐受性并有助于婴儿免疫系统的成熟，从而为被动产妇保护提供了额外的策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1481416。 doi：10.3389/fimmu.2024.1481416。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：趋化因子及其受体对于白细胞迁移到包括人牛奶在内的几个组织至关重要。在这里，我们评估了T和B淋巴细胞亚群的归因于母乳中，以应对疗养婴儿正在进行的呼吸道感染。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：血液和成熟的牛奶是从患有呼吸道感染（I组）的护士健康母亲和健康护士健康的母亲（C组）中收集的。在牛奶中评估了这些细胞中总淋巴细胞，T和B细胞，其子群数以及归巢受体CCR5，CCR6，CCR10和CXCR3的表达。还量化了母体血清和牛奶趋化因子，细胞因子，IgA和IgG抗体水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：I组的所有牛奶淋巴细胞数均高于C组。所有表达CCR5，CCR6和CXCR3的CD4 T细胞亚集在I组中均高于I组。在CD8 T-Cell子集中，CCR6和CXCR3在CCR6和CXCR3中均高于CCR6和CXCR3。 I组，虽然CCR5在I组中仅针对活化的CD8 T细胞的表达更高。 I组显示了所有CCR6+ B细胞子集的数量和CXCR3+ NAIVE B细胞和浆细胞的数量。与C的感染相比，护士的感染促进了CCL20，CXCL10，IL-6，IL-6，IL-8，IGA总IgA和IgG水平增加了。牛奶。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：护理婴儿的呼吸道感染刺激了母乳中细胞因子和趋化因子的增加，从而促进淋巴细胞的募集和激活。该过程可能会促进免疫耐受性并有助于婴儿免疫系统的成熟，从而为被动产妇保护提供了额外的策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39867906/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867906</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757141/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757141</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1481416>10.3389/fimmu.2024.1481416</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39867906</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Yingying Zheng</dc:creator><dc:creator> SimoneCorrêa-Silva</dc:creator><dc:creator>里贾纳·玛丽亚·罗德里格斯（Regina Maria Rodrigues）</dc:creator><dc:creator> eloisacorrêadesouza</dc:creator><dc:creator> Fernanda A Macaferri Da Fonseca</dc:creator><dc:creator>阿尔弗雷多·埃里亚斯·吉利奥（Alfredo Elias Gilio）</dc:creator><dc:creator> Magda Carneiro-Sampaio</dc:creator><dc:creator> Patricia Palmeira</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>婴儿呼吸道感染调节母乳淋巴细胞</dc:title><dc:identifier>PMID：39867906</dc:identifier><dc:identifier> PMC：PMC11757141</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1481416</dc:identifier></item><item><title>病例报告：在非手术条件下，成功的靶向免疫疗法针对局部晚期胰腺癌的病例</title><link/>https://pubmed.ncbi.nlm.nih.gov/39867905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description>结论：此病例突出了针对性免疫疗法治疗LAPC的潜力，特别是在非手术患者中。 NGS指导的个性化方法与免疫疗法相结合，是管理这种挑战性恶性肿瘤的传统治疗策略的有效替代方法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月10日； 15：1519186。 doi：10.3389/fimmu.2024.1519186。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：局部晚期胰腺癌（LAPC）是一种不可切除的恶性肿瘤，提出了重大的治疗挑战。 LAPC的管理仍然是一个复杂的问题，特别是在不符合手术切除的患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">案例：在这里，我们报告了一名通过病理活检诊断为LAPC的60岁妇女随后在吉西他滨，奥沙利铂和S-1（G＆S）化学疗法方案失败后接受了靶向免疫疗法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：根据下一代测序（NGS），对患者的治疗方案进行了调整，包括结合白蛋白结合的紫杉醇和Capecitabine化学疗法，以及PD-1抑制剂CAMRELIZUMAB（200 mg/cycle）（200 mg/cycle）进行六个周期。在整个治疗期间，患者始终下降手术干预。 Imaging studies, including an upper abdominal computed tomography (CT), revealed the formation of a calcified layer surrounding the cancerous tissue in the pancreatic head. Remarkably, the patient has shown stable disease and no evidence of metastasis since the initiation of targeted immunotherapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This case highlights the potential of targeted immunotherapy for the treatment of LAPC, particularly in non-surgical patients. A personalized approach guided by NGS, combined with immunotherapy, is an effective alternative to traditional treatment strategies for managing this challenging malignancy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39867905/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867905</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11760604/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11760604</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1519186>10.3389/fimmu.2024.1519186</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39867905</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Yuanbo Bi</dc:creator><dc:creator> Haotian Yv</dc:creator><dc:creator> Xiaopeng Ma</dc:creator><dc:creator> Shengxiong Chen</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions</dc:title><dc:identifier> pmid:39867905</dc:identifier><dc:identifier> pmc:PMC11760604</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1519186</dc:identifier></item><item><title> Case report: Kikuchi-Fujimoto disease presenting with persistent fever and widespread lymphadenopathy in a young adult</title><link/> https://pubmed.ncbi.nlm.nih.gov/39867904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description> Kikuchi-Fujimoto disease (KFD) is a rare, self-limiting condition typically characterized by fever and lymphadenopathy. The exact etiology remains unclear but is suspected to be associated with viral infections and autoimmune responses. This report presents the case of a 32-year-old Chinese male who was admitted with recurrent high fever, lymphadenopathy, and hepatosplenomegaly. Initial treatment was ineffective, and a lymph node biopsy subsequently confirmed the diagnosis of KFD, with evidence... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 10;15:1519988. doi: 10.3389/fimmu.2024.1519988.环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Kikuchi-Fujimoto disease (KFD) is a rare, self-limiting condition typically characterized by fever and lymphadenopathy. The exact etiology remains unclear but is suspected to be associated with viral infections and autoimmune responses. This report presents the case of a 32-year-old Chinese male who was admitted with recurrent high fever, lymphadenopathy, and hepatosplenomegaly. Initial treatment was ineffective, and a lymph node biopsy subsequently confirmed the diagnosis of KFD, with evidence of cytomegalovirus infection. Following treatment with corticosteroids, the patient&#39;s symptoms improved rapidly, and no relapse was observed during follow-up after discharge. This case highlights the diagnostic challenges of KFD, particularly in distinguishing it from lymphoma and systemic lupus erythematosus. Accurate and timely diagnosis is crucial to avoid unnecessary treatments, and long-term follow-up is recommended to monitor for potential disease progression.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39867904/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867904</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757135/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757135</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1519988>10.3389/fimmu.2024.1519988</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39867904</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Jing Ye</dc:creator><dc:creator> Qian Yu</dc:creator><dc:creator> Yan Chen</dc:creator><dc:creator> Chunping Huang</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Case report: Kikuchi-Fujimoto disease presenting with persistent fever and widespread lymphadenopathy in a young adult</dc:title><dc:identifier> pmid:39867904</dc:identifier><dc:identifier> pmc:PMC11757135</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1519988</dc:identifier></item><item><title> Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer</title><link/> https://pubmed.ncbi.nlm.nih.gov/39867903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Internal and external validation has demonstrated that the model is highly discriminative and stable and can be used to assess the risk of early recurrence in NMIBC patients and to guide clinical decision-making. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 10;15:1467527. doi: 10.3389/fimmu.2024.1467527.环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Most patients initially diagnosed with non-muscle invasive bladder cancer (NMIBC) still have frequent recurrence after urethral bladder tumor electrodesiccation supplemented with intravesical instillation therapy, and their risk of recurrence is difficult to predict. Risk prediction models used to predict postoperative recurrence in patients with NMIBC have limitations, such as a limited number of included cases and a lack of validation. Therefore, there is an urgent need to develop new models to compensate for the shortcomings and potentially provide evidence for predicting postoperative recurrence in NMIBC patients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Clinicopathologic characteristics and follow-up data were retrospectively collected from 556 patients with NMIBC who underwent transurethral resection of bladder tumors by electrocautery (TURBT) from January 2014 to December 2023 at the Affiliated Hospital of Zunyi Medical University and 167 patients with NMIBC who underwent the same procedure from January 2018 to April 2024 at the Third Affiliated Hospital of Zunyi Medical University. Independent risk factors affecting the recurrence of NMIBC were screened using the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis. Cox risk regression models and randomized survival forest (RSF) models were developed. The optimal model was selected by comparing the area under the curve (AUC) of the working characteristics of the subjects in both and presented as a column-line graph. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The study included data from 566 patients obtained from the affiliated hospital of Zunyi Medical University and 167 patients obtained from the third affiliated hospital of Zunyi Medical University. Tumor number, urine leukocytes, urine occult blood, platelets, and red blood cell distribution width were confirmed as independent risk factors predicting RFS by Lasso-Cox regression analysis. The Cox proportional risk regression model and RSF model were constructed based on Lasso, which showed good predictive efficacy in both training and validation sets, especially the traditional Cox proportional risk regression model. In addition, the discrimination, consistency, and clinical utility of the column-line graph were assessed using C-index, area under the curve (AUC), calibration curve, and decision curve analysis (DCA). Patients at high risk of recurrence can be identified early based on risk stratification. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Internal and external validation has demonstrated that the model is highly discriminative and stable and can be used to assess the risk of early recurrence in NMIBC patients and to guide clinical decision-making.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39867903/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867903</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757240/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757240</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1467527>10.3389/fimmu.2024.1467527</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39867903</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Jiajia Tang</dc:creator><dc:creator> Longmei Fan</dc:creator><dc:creator> Tianyu Huang</dc:creator><dc:creator> Rongrong Yang</dc:creator><dc:creator> Xinqi Yang</dc:creator><dc:creator> Yuanjian Liao</dc:creator><dc:creator> Mingshun Zuo</dc:creator><dc:creator> Neng Zhang</dc:creator><dc:creator> Jiangrong Zhang</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer</dc:title><dc:identifier> pmid:39867903</dc:identifier><dc:identifier> pmc:PMC11757240</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1467527</dc:identifier></item><item><title> Massive endocytosis mechanisms are involved in uptake of HIV-1 particles by monocyte-derived dendritic cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/39867902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Our results indicate the involvement of MEND mechanisms during sac-like compartment formation. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 10;15:1505840. doi: 10.3389/fimmu.2024.1505840.环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: HIV-1 exploits dendritic cells (DCs) to spread throughout the body via specific recognition of gangliosides present on the viral envelope by the CD169/Siglec-1 membrane receptor. This interaction triggers the internalization of HIV-1 within a structure known as the sac-like compartment. While the mechanism underlying sac-like compartment formation remains elusive, prior research indicates that the process is clathrin-independent and cell membrane cholesterol-dependent and involves transient disruption of cortical actin. Here, we investigate the potential involvement of massive endocytosis (MEND) in this process. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used live cell confocal imaging to measure the dimensions and dynamics of the compartment. We assessed the role of actin and cholesterol in fixed and live cells using confocal microscopy and evaluated the effect of PI3K and protein palmytoilation inhibitors during viral uptake. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Our data demonstrate extensive plasma membrane invagination based on sac-like compartment dimensions (2.9 μm in diameter and 20 μm <sup>3</sup> in volume). We showed that the cholesterol concentration doubles within the regions of viral uptake, suggesting lipid-phase separation, and that development of the sac-like compartment is accompanied by transient depolarization of cortical actin. Moreover, we observed that protein palmitoylation and PI3K inhibition reduce the sac-like compartment formation rate from 70% to 20% and 40%, respectively. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our results indicate the involvement of MEND mechanisms during sac-like compartment formation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39867902/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867902</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757119/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757119</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1505840>10.3389/fimmu.2024.1505840</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39867902</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Fernando Laguía</dc:creator><dc:creator> Jakub Chojnacki</dc:creator><dc:creator> Itziar Erkizia</dc:creator><dc:creator> María Isabel Geli</dc:creator><dc:creator> Carlos Enrich</dc:creator><dc:creator> Javier Martinez-Picado</dc:creator><dc:creator> Patricia Resa-Infante</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Massive endocytosis mechanisms are involved in uptake of HIV-1 particles by monocyte-derived dendritic cells</dc:title><dc:identifier> pmid:39867902</dc:identifier><dc:identifier> pmc:PMC11757119</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1505840</dc:identifier></item><item><title> Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma</title><link/> https://pubmed.ncbi.nlm.nih.gov/39867901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250127131342&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Gut microbiota is connected to triple therapy with local therapy combined with lenvatinib and PD-1 inhibitors for HCC. These discoveries underscore the potential of utilizing gut microbiota and intratumoral microbiota as biomarkers, as well as the possibility of triple therapy in the management of HCC. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 10;15:1500863. doi: 10.3389/fimmu.2024.1500863.环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing. Additionally, microbial community profiles of tumor tissues of patients with HCC and normal liver tissues were analyzed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In our investigation, we observed that patients with HCC who received triple therapy exhibited a notable enhancement in the abundance of Actinobacteriota and a considerable decrease in <i>Escherichia Shigella</i> . Patients who received hepatic artery infusion chemotherapy (HAIC) in combination with levatinib and PD-1 inhibitors exhibited significantly elevated levels of <i>Faecalibacterium prausnitzii</i> and <i>Bacteroides stercoris</i> in comparison to those who received transarterial chemoembolization (TACE) in combination with levatinib and PD-1 inhibitors. Furthermore, a notable decline in microbial diversity was observed within HCC tumors in comparison to normal liver tissues. The gut and intratumoral microbiota in HCC patients exhibited a high degree of similarity to the microbes present at the phylum level. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Gut microbiota is connected to triple therapy with local therapy combined with lenvatinib and PD-1 inhibitors for HCC. These discoveries underscore the potential of utilizing gut microbiota and intratumoral microbiota as biomarkers, as well as the possibility of triple therapy in the management of HCC.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39867901/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">39867901</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11757874/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250127131342&v=2.18.0.post9+e462414">PMC11757874</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1500863>10.3389/fimmu.2024.1500863</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39867901</guid><pubDate> Mon, 27 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Huangpeng Lin</dc:creator><dc:creator> Zexian Ma</dc:creator><dc:creator> Jin Li</dc:creator><dc:creator> Heping Zhu</dc:creator><dc:creator> Xuefeng Huang</dc:creator><dc:creator> Huimin Chen</dc:creator><dc:creator> Liang Tu</dc:creator><dc:creator> Yifan Lian</dc:creator><dc:creator> Yongjie Su</dc:creator><dc:date> 2025-01-27</dc:date><dc:source>免疫学领域</dc:source><dc:title>Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma</dc:title><dc:identifier> pmid:39867901</dc:identifier><dc:identifier> pmc:PMC11757874</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1500863</dc:identifier></item></channel></rss>